Navigation Links
Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit
Date:6/13/2010

Jeffrey Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with Animal Models of Pain?” at Arrowhead’s upcoming 4th Annual Pain Therapeutics Summit, to be held October 4-5, 2010 in Philadelphia, Pennsylvania.

Minneapolis, MN (PRWEB) June 10, 2010 -- Jeffrey Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with Animal Models of Pain?” at Arrowhead’s upcoming 4th Annual Pain Therapeutics Summit, to be held October 4-5, 2010 in Philadelphia, Pennsylvania.

Recent decades have seen an explosion in our understanding of the molecular and cellular underpinnings of pain, but virtually none of this knowledge has resulted in new clinical therapies. Many pain researchers believe that the problem may lie in the existing animal models of pain, which are reliable but much more complex and subtle than is commonly realized, and of questionable clinical relevance.

In addition to the disconnect between clinical symptoms and animal measures, there is a disconnect between the clinical epidemiology of pain and the types of pain being modeled in animals. Dr. Mogil’s presentation, “What’s Wrong with Animal Models of Pain?” will cover recent successes in his laboratory, involving migraine, vestibulodynia, and the development of a facial expression-based pain scale for the mouse (recently published in Nature Methods).

Jeffrey Mogil is currently the E.P. Taylor Professor of Pain Studies and the Canada Research Chair in the Genetics of Pain at McGill University. Dr. Mogil is the author of many major reviews of the subject and is the editor of The Genetics of Pain. He is a recognized authority in the fields of sex differences in pain and analgesia, and pain testing methods in the laboratory mouse. Dr. Mogil is the author of over 150 journal articles and book chapters since 1992, and has given over 190 invited lectures in that same period. He currently serves as a Section Editor (Neurobiology) at the journal Pain.

Now in its 4th year, Arrowhead’s Annual Pain Therapeutics Summit continues to attract both academic and industry leaders from around the globe to discuss pain management, preclinical and clinical development of new pain therapeutics, regulatory issues, commercialization of new pain therapies and various other topics integral to the field of pain therapeutics. For more information, go to www.paintherapeuticssummit.com or email us at enquires(at)paintherapeuticsummit(dot)com.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4116614.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
2. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
3. Horizon Therapeutics Names Dr. Jeffrey W. Sherman Executive Vice President and Chief Medical Officer
4. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
5. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
6. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
7. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
8. Dr. David Wolf, NASA Astronaut and Inventor, to Speak at BioConference Live
9. China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit
10. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
11. FMC Agricultural Products Executive Bob Trogele Speaks to the Iowa Agribusiness Showcase & Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):